The Shp2-Induced Epithelial Disorganization Defect is Reversed by HDAC6 Inhibition Independent of Cdc42
Researchers showed that oncogenic Shp2 dephosphorylates Tuba to decrease Cdc42 activation, leading to the abnormal multi-lumen formation of epithelial cells. In HER2-positive breast cancer cells, Shp2 also mediated Cdc42 repression, and HDAC6 inhibition or co-suppression of ERK/myosin II promotes normal epithelial lumen phenotype without increasing Cdc42 activity. [Nat Commun] Full Article
The Immune Microenvironment of Breast Ductal Carcinoma In Situ
Researchers profiled tumor infiltrating lymphocytes and expression of the immune checkpoint ligand programmed death ligand 1 in 27 cases of breast ductal carcinoma in situ with known estrogen receptor, progesterone receptor, and human epidermal growth factor 2 expression using tissue microarrays. [Mod Pathol] Abstract
Enhancement of Human Sodium Iodide Symporter Gene Therapy for Breast Cancer by HDAC Inhibitor Mediated Transcriptional Modulation
Scientists investigated modulation of endogenous, functional sodium iodide symporter (NIS) expression by histone deacetylase inhibitors (HDACi) in vitro and in vivo. Luciferase reporter based initial screening of six different HDACi showed 2–10 fold enhancement of NIS promoter activity in majority of the cell types tested. As a result of drug treatment, endogenous NIS transcript and protein showed profound induction in breast cancer cells. [Sci Rep] Full Article
BRCAness Revisited
Tumors that share molecular features of BRCA-mutant tumors— that is, those with ‘BRCAness’ —may also respond to similar therapeutic approaches. Several paradigm shifts require a reassessment of the concept of BRCAness, how this property is assayed and its relevance to our understanding of tumor biology and the treatment of cancer. [Nat Rev Cancer] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
INDUSTRY NEWS
Mary-Claire King, Ph.D. of University of Washington Awarded 2016 Szent-Györgyi Prize for Progress in Cancer Research
The National Foundation for Cancer Research announced that Mary-Claire King, Ph.D., University of Washington professor of medicine (medical genetics) and genome sciences has been awarded the 2016 Szent-Györgyi Prize for Progress in Cancer Research. Dr. King’s pioneering research provided the first evidence of genetic predisposition to breast cancer. [The National Foundation for Cancer Research (PR Newswire Asssociation LLC)] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!